| Name | Title | Contact Details |
|---|---|---|
Ling Zeng |
Chief Legal and Administrative Officer | Profile |
Jeffrey Kopacz |
Vice President, Intellectual Property | Profile |
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Review Services is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NatureWorks LLC is a Minnetonka, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.